Recent updates regarding Eledon's clinical pipeline indicate that its Phase 2 BESTOW extension study data displayed sustained higher kidney function and improved patient outcomes using tegoprubart compared to conventional tacrolimus regimens. Furthermore, updated investigator-initiated islet cell transplant trials evaluating tegoprubart in type 1 diabetes demonstrated stable long-term graft function and prolonged insulin independence without standard toxicity concerns.